KRYS
Price
$132.18
Change
-$4.99 (-3.64%)
Updated
May 9 closing price
Capitalization
3.96B
93 days until earnings call
XCUR
Price
$11.44
Change
+$0.06 (+0.53%)
Updated
May 9 closing price
Capitalization
71.9M
Ad is loading...

KRYS vs XCUR

Header iconKRYS vs XCUR Comparison
Open Charts KRYS vs XCURBanner chart's image
Krystal Biotech
Price$132.18
Change-$4.99 (-3.64%)
Volume$329.83K
Capitalization3.96B
Exicure
Price$11.44
Change+$0.06 (+0.53%)
Volume$5.99K
Capitalization71.9M
KRYS vs XCUR Comparison Chart
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XCUR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. XCUR commentary
May 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a StrongBuy and XCUR is a Buy.

Ad is loading...
COMPARISON
Comparison
May 10, 2025
Stock price -- (KRYS: $132.18 vs. XCUR: $11.44)
Brand notoriety: KRYS and XCUR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 100% vs. XCUR: 19%
Market capitalization -- KRYS: $3.96B vs. XCUR: $71.9M
KRYS [@Biotechnology] is valued at $3.96B. XCUR’s [@Biotechnology] market capitalization is $71.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 0 FA rating(s) are green whileXCUR’s FA Score has 0 green FA rating(s).

  • KRYS’s FA Score: 0 green, 5 red.
  • XCUR’s FA Score: 0 green, 5 red.
According to our system of comparison, KRYS is a better buy in the long-term than XCUR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 4 TA indicator(s) are bullish while XCUR’s TA Score has 6 bullish TA indicator(s).

  • KRYS’s TA Score: 4 bullish, 6 bearish.
  • XCUR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, XCUR is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а -20.45% price change this week, while XCUR (@Biotechnology) price change was +6.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.24%. For the same industry, the average monthly price growth was +9.39%, and the average quarterly price growth was -13.47%.

Reported Earning Dates

KRYS is expected to report earnings on Aug 11, 2025.

XCUR is expected to report earnings on Aug 13, 2024.

Industries' Descriptions

@Biotechnology (-6.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($3.96B) has a higher market cap than XCUR($71.9M). KRYS has higher P/E ratio than XCUR: KRYS (33.45) vs XCUR (0.19). KRYS (-15.626) and XCUR (-16.313) have similar YTD gains . KRYS has higher annual earnings (EBITDA): 110M vs. XCUR (-3.17M). KRYS has more cash in the bank: 598M vs. XCUR (343K). XCUR has less debt than KRYS: XCUR (6.13M) vs KRYS (7.26M). KRYS has higher revenues than XCUR: KRYS (291M) vs XCUR (500K).
KRYSXCURKRYS / XCUR
Capitalization3.96B71.9M5,513%
EBITDA110M-3.17M-3,468%
Gain YTD-15.626-16.31396%
P/E Ratio33.450.1917,901%
Revenue291M500K58,200%
Total Cash598M343K174,344%
Total Debt7.26M6.13M118%
FUNDAMENTALS RATINGS
KRYS vs XCUR: Fundamental Ratings
KRYS
XCUR
OUTLOOK RATING
1..100
5650
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
36100
SMR RATING
1..100
6695
PRICE GROWTH RATING
1..100
8334
P/E GROWTH RATING
1..100
96100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XCUR's Valuation (70) in the null industry is in the same range as KRYS (73) in the Pharmaceuticals Major industry. This means that XCUR’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for XCUR (100) in the null industry. This means that KRYS’s stock grew somewhat faster than XCUR’s over the last 12 months.

KRYS's SMR Rating (66) in the Pharmaceuticals Major industry is in the same range as XCUR (95) in the null industry. This means that KRYS’s stock grew similarly to XCUR’s over the last 12 months.

XCUR's Price Growth Rating (34) in the null industry is somewhat better than the same rating for KRYS (83) in the Pharmaceuticals Major industry. This means that XCUR’s stock grew somewhat faster than KRYS’s over the last 12 months.

KRYS's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as XCUR (100) in the null industry. This means that KRYS’s stock grew similarly to XCUR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSXCUR
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 12 days ago
77%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XCUR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EPU45.330.31
+0.69%
iShares MSCI Peru ETF
FXED17.740.03
+0.17%
Sound Enhanced Fixed Income ETF
FSCO7.090.01
+0.14%
FS Credit Opportunities Corp
CADJPY104.85N/A
N/A
Canadian Dollar - Japan Yen
VNM12.49-0.11
-0.87%
VanEck Vietnam ETF

XCUR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XCUR has been loosely correlated with XFOR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if XCUR jumps, then XFOR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XCUR
1D Price
Change %
XCUR100%
+0.53%
XFOR - XCUR
34%
Loosely correlated
+2.43%
ALNY - XCUR
26%
Poorly correlated
-2.79%
NNVC - XCUR
25%
Poorly correlated
-6.38%
PLX - XCUR
25%
Poorly correlated
-40.48%
KRYS - XCUR
24%
Poorly correlated
-3.64%
More